CORRECTION

The story, "Wyeth, Progenics Begin Study of Oral Methylnal trexone," in the March 12 issue of FDAnews Drug Pipeline Alert should have stated that Wyeth is beginning a Phase II trial of a new formulation of the drug for the treatment of opioid-induced constipation and that Wyeth and Progencis are on schedule to submit a new drug application in March for the subcutaneous form in the palliative care setting and for the intravenous form in late 2007 or early 2008.